{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T21:08:36Z","timestamp":1791320916291,"version":"4.3.1"},"reference-count":134,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T00:00:00Z","timestamp":1737331200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>The treatment landscape for advanced melanoma has transformed significantly with the advent of BRAF and MEK inhibitors (BRAF\/MEKi) targeting BRAFV600 mutations, as well as immune checkpoint inhibitors (ICI) like anti-PD-1 monotherapy or its combinations with anti-CTLA-4 or anti-LAG-3. Despite that, many patients still do not benefit from these treatments at all or develop resistance mechanisms. Therefore, prognostic and predictive biomarkers are needed to identify patients who should switch or escalate their treatment strategies or initiate an intensive follow-up. In melanoma, liquid biopsy has shown promising results, with a potential role in predicting relapse in resected high-risk patients or in disease monitoring during the treatment of advanced disease. Several components in peripheral blood have been analyzed, such as circulating tumor cells (CTCs), cell-free DNA (cfDNA), and circulant tumoral DNA (ctDNA), which have turned out to be particularly promising. To analyze ctDNA in blood, different techniques have proven to be useful, including digital droplet polymerase chain reaction (ddPCR) to detect specific mutations and, more recently, next-generation sequencing (NGS) techniques, which allow analyzing a broader repertoire of the mutation landscape of each patient. In this review, our goal is to update the current understanding of liquid biopsy, focusing on the use of ctDNA as a biological material in the daily clinical management of melanoma patients, in particular those with advanced disease treated with ICI.<\/jats:p>","DOI":"10.3390\/ijms26020861","type":"journal-article","created":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T06:53:32Z","timestamp":1737442412000},"page":"861","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Detection of Circulating Tumor DNA in Liquid Biopsy: Current Techniques and Potential Applications in Melanoma"],"prefix":"10.3390","volume":"26","author":[{"given":"Clara","family":"Mart\u00ednez-Vila","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Althaia Xarxa Assistencial Universit\u00e0ria de Manresa, Dr. Joan Soler, 1\u20133, 08243 Manresa, Spain"},{"name":"Programa de Doctorat en Medicina i Recerca Translacional, Facultat de Medicina, Universitat de Barcelona, 08036 Barcelona, Spain"},{"name":"Institut de Recerca i Innovaci\u00f3 en Ci\u00e8ncies de la Vida i de la Salut a la Catalunya Central (IRIS-CC), Roda 70, 08500 Vic, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7226-6567","authenticated-orcid":false,"given":"Cristina","family":"Teixido","sequence":"additional","affiliation":[{"name":"Department of Pathology, Hospital Cl\u00ednic of Barcelona, University of Barcelona, Villarroel 170, 08036 Barcelona, Spain"},{"name":"August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Rossell\u00f3 149, 08036 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3452-7607","authenticated-orcid":false,"given":"Francisco","family":"Aya","sequence":"additional","affiliation":[{"name":"August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Rossell\u00f3 149, 08036 Barcelona, Spain"},{"name":"Department of Medical Oncology, Hospital Cl\u00ednic of Barcelona, University of Barcelona, Villarroel 170, 08036 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Mart\u00edn","sequence":"additional","affiliation":[{"name":"August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Rossell\u00f3 149, 08036 Barcelona, Spain"},{"name":"Department of Medical Oncology, Hospital Cl\u00ednic of Barcelona, University of Barcelona, Villarroel 170, 08036 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Europa Azucena","family":"Gonz\u00e1lez-Navarro","sequence":"additional","affiliation":[{"name":"August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Rossell\u00f3 149, 08036 Barcelona, Spain"},{"name":"Department of Immunology, Hospital Cl\u00ednic of Barcelona, University of Barcelona, Villarroel 170, 08036 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3460-0384","authenticated-orcid":false,"given":"Llucia","family":"Alos","sequence":"additional","affiliation":[{"name":"Department of Pathology, Hospital Cl\u00ednic of Barcelona, University of Barcelona, Villarroel 170, 08036 Barcelona, Spain"},{"name":"August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Rossell\u00f3 149, 08036 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0647-3058","authenticated-orcid":false,"given":"Natalia","family":"Castrejon","sequence":"additional","affiliation":[{"name":"Department of Pathology, Hospital Cl\u00ednic of Barcelona, University of Barcelona, Villarroel 170, 08036 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2896-1957","authenticated-orcid":false,"given":"Ana","family":"Arance","sequence":"additional","affiliation":[{"name":"August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Rossell\u00f3 149, 08036 Barcelona, Spain"},{"name":"Department of Medical Oncology, Hospital Cl\u00ednic of Barcelona, University of Barcelona, Villarroel 170, 08036 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,1,20]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/nature00766","article-title":"Mutations of the BRAF gene in human cancer","volume":"417","author":"Davies","year":"2002","journal-title":"Nature"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1158\/0008-5472.CAN-13-2625","article-title":"Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence","volume":"74","author":"Nissan","year":"2014","journal-title":"Cancer Res."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Teixido, C., Castillo, P., Martinez-Vila, C., Arance, A., and Alos, L. (2021). Molecular Markers and Targets in Melanoma. Cells, 10.","DOI":"10.3390\/cells10092320"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1104621","article-title":"Ipilimumab plus dacarbazine for previously untreated metastatic melanoma","volume":"364","author":"Robert","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1001\/jamaoncol.2018.4514","article-title":"Survival Outcomes in Patients with Previously Untreated BRAF Wild-Type Advanced Melanoma Treated with Nivolumab Therapy: Three-Year Follow-up of a Randomized Phase 3 Trial","volume":"5","author":"Ascierto","year":"2019","journal-title":"JAMA Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"3998","DOI":"10.1200\/JCO.22.01599","article-title":"Seven-Year Follow-Up of the Phase III KEYNOTE-006 Study: Pembrolizumab Versus Ipilimumab in Advanced Melanoma","volume":"41","author":"Robert","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1200\/JCO.21.02229","article-title":"Long-Term Outcomes with Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients with Advanced Melanoma","volume":"40","author":"Wolchok","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa2407417","article-title":"CheckMate 067 Investigators. Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma","volume":"392","author":"Wolchok","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"EVIDoa2200239","DOI":"10.1056\/EVIDoa2200239","article-title":"Overall Survival and Response with Nivolumab and Relatlimab in Advanced Melanoma","volume":"2","author":"Long","year":"2023","journal-title":"NEJM Evid."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/S0140-6736(12)60868-X","article-title":"Dabrafenib in BRAF-mutated metastatic melanoma: A multicentre, open-label, phase 3 randomised con-trolled trial","volume":"380","author":"Hauschild","year":"2012","journal-title":"Lancet"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1093\/annonc\/mdz221","article-title":"Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E\/K-mutant melanoma: Long-term survival and safety analysis of a phase 3 study","volume":"30","author":"Long","year":"2019","journal-title":"Ann. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/S1470-2045(16)30122-X","article-title":"Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): Updated efficacy results from a randomised, double-blind, phase 3 trial","volume":"17","author":"Ascierto","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_14","first-page":"2301","article-title":"COLUMBUS 5-Year Update: A Randomized, Open-Label, Phase III Trial of Encorafenib Plus Binimetinib Versus Vemurafenib or Encorafenib in Patients with BRAF V600-Mutant Melanoma","volume":"41","author":"Dummer","year":"2023","journal-title":"Clin. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1200\/JCO.23.02355","article-title":"Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma: Final analysis of distant metastasis-free survival in the phase III KEYNOTE-716 study","volume":"42","author":"Luke","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1038\/s41591-023-02583-2","article-title":"Adjuvant nivolumab in resected stage IIB\/C melanoma: Primary results from the randomized, phase 3 CheckMate 76K trial","volume":"29","author":"Kirkwood","year":"2023","journal-title":"Nat. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"3352","DOI":"10.1158\/1078-0432.CCR-22-3145","article-title":"Adjuvant Nivolumab versus Ipilimumab in Resected Stage III\/IV Melanoma: 5-Year Efficacy and Biomarker Results from CheckMate 238","volume":"29","author":"Larkin","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1245\/s10434-010-0985-4","article-title":"The American Joint Committee on Cancer: The 7th edition of the AJCC cancer staging manual and the future of TNM","volume":"17","author":"Edge","year":"2010","journal-title":"Ann. Surg. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"EVIDoa2200214","DOI":"10.1056\/EVIDoa2200214","article-title":"Five-Year Analysis of Adjuvant Pembrolizumab or Placebo in Stage III Melanoma","volume":"1","author":"Eggermont","year":"2022","journal-title":"NEJM Evid."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa2005493","article-title":"Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma","volume":"383","author":"Dummer","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"S1408","DOI":"10.1016\/j.annonc.2022.08.039","article-title":"LBA6 Neoadjuvant versus adjuvant pembrolizumab for resected stage III-IV melanoma (SWOG S1801)","volume":"33","author":"Patel","year":"2022","journal-title":"Ann. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1056\/NEJMoa2402604","article-title":"Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma","volume":"391","author":"Blank","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.annonc.2024.11.006","article-title":"ESMO Guidelines Committee. Cutaneous melanoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"36","author":"Amaral","year":"2024","journal-title":"Ann. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1158\/1535-7163.MCT-14-0983","article-title":"PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy","volume":"14","author":"Patel","year":"2015","journal-title":"Mol. Cancer Ther."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"351","DOI":"10.5858\/arpa.2015-0509-SA","article-title":"PD-L1 and Lung Cancer: The Era of Precision-ish Medicine?","volume":"140","author":"Borczuk","year":"2016","journal-title":"Arch. Pathol. Lab. Med."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Schmidt, L.H., K\u00fcmmel, A., G\u00f6rlich, D., Mohr, M., Br\u00f6ckling, S., Mikesch, J.H., and Hartmann, W. (2015). PD-1 and PD-L1 Expression in NSCLC Indicate a Favorable Prognosis in Defined Subgroups. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0136023"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1158\/0008-5472.CAN-11-3218","article-title":"Immunotype and immunohistologic characteristics of tumor-infiltrating immune cells are associated with clinical outcome in metastatic melanoma","volume":"72","author":"Erdag","year":"2012","journal-title":"Cancer Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/s41571-022-00686-2","article-title":"The multiple roles of LDH in cancer","volume":"19","author":"Claps","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Vanni, I., Tanda, E.T., Spagnolo, F., Andreotti, V., Bruno, W., and Ghiorzo, P. (2020). The current state of molecular testing in the BRAF-mutated melanoma landscape. Front. Mol. Biosci., 7.","DOI":"10.3389\/fmolb.2020.00113"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1245\/s10434-018-6513-7","article-title":"Melanoma Staging: American Joint Committee on Cancer (AJCC) 8th Edition and Beyond","volume":"25","author":"Gershenwald","year":"2018","journal-title":"Ann. Surg. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"207ps14","DOI":"10.1126\/scitranslmed.3006305","article-title":"Going with the flow: From circulating tumor cells to DNA","volume":"5","author":"Bidard","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"ref_32","first-page":"309","article-title":"cfDNA analysis from blood in melanoma","volume":"3","author":"Rosell","year":"2015","journal-title":"Ann. Transl. Med."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Castrejon, N., Martin, R., Carrasco, A., Castillo, P., Garcia, A., Albero-Gonz\u00e1lez, R., Garc\u00eda, M., Marginet, M., Palau, N., and Hern\u00e1ndez, M. (2024). Feasibility and Impact of Embedding an Extended DNA and RNA Tissue-Based Sequencing Panel for the Routine Care of Patients with Advanced Melanoma in Spain. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25136942"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1158\/1078-0432.CCR-1169-3","article-title":"Incidence of BRAF oncogene mutation and clinical relevance for primary cutaneous melanomas","volume":"10","author":"Shinozaki","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.phrs.2016.03.007","article-title":"Targeting mutant NRAS signaling pathways in melanoma","volume":"107","author":"Vu","year":"2016","journal-title":"Pharmacol. Res."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"4014","DOI":"10.1002\/cncr.26724","article-title":"NRAS mutation status is an independent prognostic factor in metastatic melanoma","volume":"118","author":"Jakob","year":"2012","journal-title":"Cancer"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1126\/science.1230062","article-title":"TERT promoter mutations in familial and sporadic melanoma","volume":"339","author":"Horn","year":"2023","journal-title":"Science"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1111\/pcmr.12500","article-title":"High TERT promoter mutation frequency in non-acral cutaneous metastatic melanoma","volume":"29","author":"Ekedahl","year":"2016","journal-title":"Pigment. Cell Melanoma Res."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1056\/NEJMoa050092","article-title":"Distinct Sets of Genetic Alterations in Melanoma","volume":"353","author":"Curtin","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_40","first-page":"1659","article-title":"DNA fragments in the blood plasma of cancer patients: Quantitations and evidence for their origin from apoptotic and necrotic cells","volume":"61","author":"Jahr","year":"2021","journal-title":"Cancer Res."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.cell.2015.11.050","article-title":"Cell-free DNA comprises an in vivo nucleosome footprint that informs its tissues-of-origin","volume":"164","author":"Snyder","year":"2016","journal-title":"Cell"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"42008","DOI":"10.18632\/oncotarget.5788","article-title":"Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma","volume":"6","author":"Gray","year":"2015","journal-title":"Oncotarget"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/j.jtho.2017.04.003","article-title":"Plasma ctDNA analysis for detection of the EGFR T790M mutation in patients with advanced non\u2013small cell lung cancer","volume":"12","author":"Jenkins","year":"2017","journal-title":"J. Thorac. Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1038\/nm.1789","article-title":"Circulating mutant DNA to assess tumor dynamics","volume":"14","author":"Diehl","year":"2008","journal-title":"Nat. Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/nmeth.2027","article-title":"Digital PCR hits its stride","volume":"9","author":"Baker","year":"2012","journal-title":"Nat. Methods"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"3209","DOI":"10.1158\/1078-0432.CCR-12-0871","article-title":"BEAMing up personalized medicine: Mutation detection in blood","volume":"18","author":"Richardson","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1158\/1078-0432.CCR-15-0321","article-title":"Correlation of BRAF Mutation Status in Circulating-Free DNA and Tumor and Association with Clinical Outcome across Four BRAFi and MEKi Clinical Trials","volume":"22","author":"Gagnon","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1177\/2472630317705680","article-title":"Digital assays part I: Partition ing statistics and digital PCR","volume":"22","author":"Basu","year":"2017","journal-title":"SLAS Technol."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Pinheiro, L., and Emslie, K.R. (2018). Basic concepts and validation of digital PCR measurements. Digital PCR, Springer.","DOI":"10.1007\/978-1-4939-7778-9_2"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"8604","DOI":"10.1021\/ac202028g","article-title":"High-throughput droplet digital PCR system for absolute quantitation of DNA copy number","volume":"83","author":"Hindson","year":"2011","journal-title":"Anal. Chem."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.bdq.2014.08.001","article-title":"Determining lower limits of detection of digital PCR assays for cancer-related gene mutations","volume":"1","author":"Milbury","year":"2014","journal-title":"Biomol. Detect. Quantif."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1373\/clinchem.2014.230235","article-title":"Quantitative cell- free circulating BRAFV600E mutation analysis by use of droplet digital PCR in the follow-up of patients with melanoma being treated with BRAF inhibitors","volume":"61","author":"Sanmamed","year":"2015","journal-title":"Clin. Chem."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1038\/s41467-018-04001-5","article-title":"Whole-exome sequencing of cell-free DNA and circulating tumor cells in multiple myeloma","volume":"9","author":"Manier","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"9530","DOI":"10.1073\/pnas.1105422108","article-title":"Detection and quantification of rare mutations with massively parallel sequencing","volume":"108","author":"Kinde","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Shu, Y., Wu, X., Tong, X., Wang, X., Chang, Z., Mao, Y., Chen, X., Sun, J., Wang, Z., and Hong, Z. (2017). Circulating tumor DNA mutation profiling by targeted next generation sequencing provides guidance for personalized treatments in multiple cancer types. Sci. Rep., 7.","DOI":"10.1038\/s41598-017-00520-1"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40257-018-0398-x","article-title":"Monitoring Melanoma Using Circulating Free DNA","volume":"20","author":"Diefenbach","year":"2019","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"FSO295","DOI":"10.4155\/fsoa-2017-0140","article-title":"Kinetics of circulating cell-free DNA for biomedical applications: Critical appraisal of the literature","volume":"4","author":"Khier","year":"2018","journal-title":"Future Sci. OA"},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Lanman, R.B., Mortimer, S.A., Zill, O.A., Sebisanovic, D., Lopez, R., Blau, S., Collisson, E.A., Divers, S.G., Hoon, D.S.B., and Kopetz, E.S. (2015). Analytical and Clinical Validation of a Digital Sequencing Panel for Quantitative, Highly Accurate Evaluation of Cell-Free Circulating Tumor DNA. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0140712"},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Woodhouse, R., Li, M., Hughes, J., Delfosse, D., Skoletsky, J., Ma, P., Meng, W., Dewal, N., Milbury, C., and Clark, T. (2020). Clinical and analytical validation of FoundationOne Liquid CDx, a novel 324-Gene cfDNA-based comprehensive genomic profiling assay for cancers of solid tumor origin. PLoS ONE, 15.","DOI":"10.1371\/journal.pone.0237802"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/nature22364","article-title":"Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution","volume":"545","author":"Abbosh","year":"2017","journal-title":"Nature"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"4255","DOI":"10.1158\/1078-0432.CCR-18-3663","article-title":"Personalized Detection of Circulating Tumor DNA Antedates Breast Cancer Metastatic Recurrence","volume":"25","author":"Coombes","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1038\/s43018-020-0096-5","article-title":"Personalised circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumab","volume":"38","author":"Bratman","year":"2020","journal-title":"Nat. Cancer"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1038\/s41416-022-01716-7","article-title":"Liquid BIOpsy for MiNimal RESidual DiSease Detection in Head and Neck Squamous Cell Carcinoma (LIONESS)-a personalised circulating tumour DNA analysis in head and neck squamous cell carcinoma","volume":"126","author":"Flach","year":"2022","journal-title":"Br. J. Cancer"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"e00699","DOI":"10.1016\/j.heliyon.2018.e00699","article-title":"Factors that influence quality and yield of circulating-free DNA: A systematic review of the methodology literature","volume":"4","author":"Trigg","year":"2018","journal-title":"Heliyon"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"6159","DOI":"10.1093\/nar\/gkq421","article-title":"Origin and quantification of circulating DNA in mice with human colorectal cancer xenografts","volume":"38","author":"Thierry","year":"2010","journal-title":"Nucleic Acids Res."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1038\/s41571-020-00457-x","article-title":"Liquid biopsy enters the clinic\u2014Implementation issues and future challenges","volume":"18","author":"Ignatiadis","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"6499","DOI":"10.1007\/s00216-014-7835-3","article-title":"Towards standardisation of cell-free DNA measurement in plasma: Controls for extraction efficiency, fragment size bias and quantification","volume":"406","author":"Devonshire","year":"2014","journal-title":"Anal. Bioanal. Chem."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/978-1-4939-9773-2_7","article-title":"Validation of Circulating Tumor DNA Assays for Detection of Metastatic Melanoma","volume":"2055","author":"Syeda","year":"2020","journal-title":"Methods Mol. Biol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/j.clinbiochem.2015.02.014","article-title":"EDTA-mediated inhibition of DNases protects circulating cell-free DNA from ex vivo degradation in blood samples","volume":"48","author":"Barra","year":"2015","journal-title":"Clin. Biochem."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1002\/cam4.1184","article-title":"Preanalytical blood sample workup for cell-free DNA analysis using Droplet Digital PCR for future molecular cancer diagnostics","volume":"6","author":"Linders","year":"2017","journal-title":"Cancer Med."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1373\/clinchem.2003.026013","article-title":"EDTA is a better anticoagulant than heparin or citrate for delayed blood processing for plasma DNA analysis","volume":"50","author":"Lam","year":"2004","journal-title":"Clin. Chem."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"224ra24","DOI":"10.1126\/scitranslmed.3007094","article-title":"Detection of circulating tumor DNA in early- and late-stage human malignancies","volume":"6","author":"Bettegowda","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1007\/s40291-023-00651-4","article-title":"Dynamic ctDNA Mutational Complexity in Patients with Melanoma Receiving Immunotherapy","volume":"27","author":"Fitzgerald","year":"2023","journal-title":"Mol. Diagn. Ther."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1093\/clinchem\/47.9.1607","article-title":"Effects of blood-processing protocols on fetal and total DNA quantification in maternal plasma","volume":"47","author":"Chiu","year":"2001","journal-title":"Clin. Chem."},{"key":"ref_75","unstructured":"National Cancer Institute (2024). NCI Biospecimen Evidence-Based Practices (BEBP)\u2014Cell-Free DNA: Biospecimen Collection and Processing V1, National Cancer Institute."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.stem.2018.01.011","article-title":"Clonal hematopoiesis and evolution to hematopoietic malignancies","volume":"22","author":"Bowman","year":"2018","journal-title":"Cell Stem Cell"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"4437","DOI":"10.1158\/1078-0432.CCR-18-0143","article-title":"False positive plasma genotyping due to clonal hematopoiesis","volume":"24","author":"Hu","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s11523-017-0491-8","article-title":"Circulating Tumor DNA Measurement by Picoliter Droplet-Based Digital PCR and Vemurafenib Plasma Concentrations in Patients with Advanced BRAF-Mutated Melanoma","volume":"12","author":"Garlan","year":"2017","journal-title":"Target. Oncol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1158\/1078-0432.CCR-13-2482","article-title":"Noninvasive detection of response and re-sistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cellfree plasma DNA","volume":"20","author":"Oxnard","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1002\/1878-0261.13557","article-title":"Correlation between variant allele frequency and mean tumor molecules with tumor burden in patients with solid tumors","volume":"18","author":"Kalashnikova","year":"2023","journal-title":"Mol. Oncol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1093\/annonc\/mdz075","article-title":"Pre-operative ctDNA predicts survival in high-risk stage III cutaneous melanoma patients","volume":"30","author":"Lee","year":"2019","journal-title":"Ann. Oncol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1093\/annonc\/mdx717","article-title":"Circulating tumor DNA predicts survival in patients with resected high-risk stage II\/III melanoma","volume":"29","author":"Lee","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1093\/annonc\/mdz048","article-title":"Prediction and monitoring of relapse in stage III melanoma using circulating tumor DNA","volume":"30","author":"Tan","year":"2019","journal-title":"Ann. Oncol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"S356","DOI":"10.1016\/j.annonc.2022.07.914","article-title":"788O\u2014Association of pre-treatment ctDNA with disease recurrence and clinical and translational factors in patients with stage IIIB-D\/IV melanoma treated with adjuvant immunotherapy(CheckMate 915)","volume":"33","author":"Long","year":"2022","journal-title":"Ann. Oncol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"103978","DOI":"10.1016\/j.esmoop.2024.103978","article-title":"Bespoke ctDNA for longitudinal detection of molecular residual disease in high-risk melanoma patients","volume":"9","author":"Genta","year":"2024","journal-title":"ESMO Open"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"36238","DOI":"10.18632\/oncotarget.26343","article-title":"Monitoring BRAF and NRAS mutations with cell-free cir-culating tumor DNA from metastatic melanoma patients","volume":"9","author":"Ilie","year":"2018","journal-title":"Oncotarget"},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"Sobczuk, P., Kozak, K., Kope\u0107, S., Rogala, P., \u015awitaj, T., Kose\u0142a-Paterczyk, H., Gos, A., Tysarowski, A., and Rutkowski, P. (2022). The Use of ctDNA for BRAF Mutation Testing in Routine Clinical Practice in Patients with Advanced Melanoma. Cancers, 14.","DOI":"10.3390\/cancers14030777"},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Giunta, E.F., De Falco, V., Vitiello, P.P., Guerrera, L.P., Suarato, G., Napolitano, R., Perrone, A., Argenziano, G., Franco, R., and Caraglia, M. (2022). Clinical Utility of Liquid Biopsy to Detect BRAF and NRAS Mutations in Stage III\/IV Melanoma Patients by Using Real-Time PCR. Cancers, 14.","DOI":"10.3390\/cancers14133053"},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"McEvoy, A.C., Warburton, L., Al-Ogaili, Z., Celliers, L., Calapre, L., Pereira, M.R., Khattak, M.A., Meniawy, T.M., Millward, M., and Ziman, M. (2018). Correlation between circulating tumor DNA and metabolic tumor burden in metastatic melanoma patients. BMC Cancer, 18.","DOI":"10.1186\/s12885-018-4637-6"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.16.00009","article-title":"Circulating Tumor DNA Analysis and Functional Imaging Provide Complementary Approaches for Comprehensive Disease Monitoring in Metastatic Melanoma","volume":"1","author":"Wong","year":"2017","journal-title":"JCO Precis. Oncol."},{"key":"ref_91","doi-asserted-by":"crossref","unstructured":"Marczynski, G.T., Laus, A.C., Dos Reis, M.B., Reis, R.M., and Vazquez, V.L. (2020). Circulating tumor DNA (ctDNA) detection is associated with shorter progression-free survival in advanced melanoma patients. Sci. Rep., 10.","DOI":"10.1038\/s41598-020-75792-1"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"78890","DOI":"10.18632\/oncotarget.20354","article-title":"Sensitive droplet digital PCR method for detection of TERT promoter mutations in cell free DNA from patients with metastatic melanoma","volume":"8","author":"McEvoy","year":"2017","journal-title":"Oncotarget"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1002\/1878-0261.12391","article-title":"Locus-specific concordance of genomic alterations between tissue and plasma circulating tumor DNA in metastatic melanoma","volume":"13","author":"Calapre","year":"2019","journal-title":"Mol. Oncol."},{"key":"ref_94","first-page":"PO.17.00225","article-title":"Multiplex Gene Profiling of Cell-Free DNA in Patients with Metastatic Melanoma for Monitoring Disease","volume":"2","author":"Lin","year":"2018","journal-title":"JCO Precis. Oncol."},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"Diefenbach, R.J., Lee, J.H., Menzies, A.M., Carlino, M.S., Long, G.V., Saw, R.P.M., Howle, J.R., Spillane, A.J., Scolyer, R.A., and Kefford, R.F. (2020). Design and Testing of a Custom Melanoma Next Generation Sequencing Panel for Analysis of Circulating Tumor DNA. Cancers, 12.","DOI":"10.3390\/cancers12082228"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1093\/annonc\/mdx026","article-title":"Circulating tumor DNA predicts response to anti-PD1 antibodies in metastatic melanoma","volume":"28","author":"Lee","year":"2017","journal-title":"Ann. Oncol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1001\/jamaoncol.2017.5332","article-title":"Association Between Circulating Tumor DNA and Pseudoprogression in Patients with Metastatic Melanoma Treated with Anti-Programmed Cell Death 1 Antibodies","volume":"4","author":"Lee","year":"2018","journal-title":"JAMA Oncol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1186\/s12967-019-2051-8","article-title":"Undetectable circulating tumor DNA (ctDNA) levels correlate with favorable outcome in metastatic melanoma patients treated with anti-PD1 therapy","volume":"17","author":"Seremet","year":"2019","journal-title":"J. Transl. Med."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"4064","DOI":"10.1158\/1078-0432.CCR-19-3926","article-title":"Longitudinal Monitoring of ctDNA in Patients with Melanoma and Brain Metastases Treated with Immune Checkpoint Inhibitors","volume":"26","author":"Lee","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_100","doi-asserted-by":"crossref","unstructured":"Herbreteau, G., Vall\u00e9e, A., Knol, A.-C., Th\u00e9oleyre, S., Qu\u00e9reux, G., Fr\u00e9nard, C., Varey, E., Hofman, P., Khammari, A., and Dr\u00e9no, B. (2020). Circulating Tumour DNA Is an Independent Prognostic Biomarker for Survival in Metastatic BRAF or NRAS-Mutated Mela-noma Patients. Cancers, 12.","DOI":"10.3390\/cancers12071871"},{"key":"ref_101","doi-asserted-by":"crossref","unstructured":"Mart\u00ednez-Vila, C., Gonz\u00e1lez-Navarro, E.A., Teixido, C., Martin, R., Aya, F., Juan, M., and Arance, A. (2024). Lymphocyte T Subsets and Outcome of Immune Check-point Inhibitors in Melanoma Patients: An Oncologist\u2019s Perspective on Current Knowledge. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25179506"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.cell.2020.09.001","article-title":"Noninvasive Early Identification of Therapeutic Benefit from Immune Checkpoint Inhibition","volume":"183","author":"Nabet","year":"2020","journal-title":"Cell"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"5729","DOI":"10.1158\/1078-0432.CCR-17-1439","article-title":"Hypermutated Circulating Tumor DNA: Correlation with Response to Checkpoint Inhibitor-Based Immunotherapy","volume":"23","author":"Khagi","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1038\/s41591-022-02163-w","article-title":"Persistent mutation burden drives sustained anti-tumor immune responses","volume":"29","author":"Niknafs","year":"2023","journal-title":"Nat. Med."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1186\/s40425-019-0659-0","article-title":"Tumor mutation burden and circulating tumor DNA in combined CTLA-4 and PD-1 antibody therapy in metastatic melanoma\u2014Results of a prospective biomarker study","volume":"7","author":"Forschner","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1158\/2326-6066.CIR-16-0143","article-title":"Targeted next generation sequencing identifies markers of response to PD-1 blockade","volume":"4","author":"Johnson","year":"2016","journal-title":"Cancer Immunol. Res."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1038\/s41591-024-02877-z","article-title":"Neoadjuvant nivolumab or nivolumab plus LAG-3 inhibitor relatlimab in resectable esophageal\/gastroesophageal junction cancer: A phase Ib trial and ctDNA analyses","volume":"30","author":"Kelly","year":"2024","journal-title":"Nat. Med."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1002\/cncr.34716","article-title":"Circulating tumor DNA-based molecular residual disease detection for treatment monitoring in advanced melanoma patients","volume":"129","author":"Eroglu","year":"2023","journal-title":"Cancer"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"8750","DOI":"10.1038\/s41467-024-52923-0","article-title":"Tumour-informed liquid biopsies to monitor advanced melanoma patients under immune checkpoint inhibition","volume":"15","author":"Schroeder","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s12967-016-0852-6","article-title":"Quantitative assessment of BRAF V600 mutant circulating cell-free tumor DNA as a tool for therapeutic monitoring in metastatic melanoma patients treated with BRAF\/MEK inhibitors","volume":"14","author":"Schreuer","year":"2016","journal-title":"J. Transl. Med."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1097\/CMR.0000000000000187","article-title":"BRAF mutation analysis in circulating free tumor DNA of melanoma patients treated with BRAF inhibitors","volume":"25","author":"Manzano","year":"2015","journal-title":"Melanoma Res."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1097\/CMR.0000000000000432","article-title":"Early evolution of BRAFV600 status in the blood of melanoma patients correlates with clinical outcome and identifies patients refractory to therapy","volume":"28","author":"Casas","year":"2018","journal-title":"Melanoma Res."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"5017","DOI":"10.2147\/OTT.S248237","article-title":"Circulating Tumor DNA Correlates with Outcome in Metastatic Melanoma Treated by BRAF and MEK Inhibitors\u2014Results of a Prospective Biomarker Study","volume":"13","author":"Forschner","year":"2020","journal-title":"Onco Targets Ther."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1158\/0008-5472.CAN-21-1718","article-title":"Current and Future Clinical Applications of ctDNA in Immuno-Oncology","volume":"82","author":"Stadler","year":"2022","journal-title":"Cancer Res."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/S1470-2045(20)30726-9","article-title":"Circulating tumor DNA in patients with advanced melanoma treated with dabrafenib or dabrafenib plus trametinib: A clinical validation study","volume":"22","author":"Syeda","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1158\/2159-8290.CD-15-1336","article-title":"Application of Sequencing, Liquid Biopsies, and Patient-Derived Xenografts for Personalised Medicine in Melanoma","volume":"6","author":"Girotti","year":"2016","journal-title":"Cancer Discov."},{"key":"ref_117","doi-asserted-by":"crossref","unstructured":"Warburton, L., Meniawy, T.M., Calapre, L., Pereira, M., McEvoy, A., Ziman, M., Gray, E.S., and Millward, M. (2020). Stopping targeted therapy for complete responders in advanced BRAF mutant melanoma. Sci. Rep., 10.","DOI":"10.1038\/s41598-020-75837-5"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1002\/onco.13926","article-title":"Liquid Biopsy and Radiological Response Predict Outcomes Following Discontinuation of Targeted Therapy in Patients with BRAF Mutated Melanoma","volume":"26","author":"Randon","year":"2021","journal-title":"Oncologist"},{"key":"ref_119","doi-asserted-by":"crossref","unstructured":"Kaisaki, P.J., Cutts, A., Popitsch, N., Camps, C., Pentony, M.M., Wilson, G., Page, S., Kaur, K., Vavoulis, D., and Henderson, S. (2016). Targeted Next-Generation Sequencing of Plasma DNA from Cancer Pa-tients: Factors Influencing Consistency with Tumor DNA and Prospective Investigation of Its Utility for Diagnosis. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0162809"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2017.10.029","article-title":"Plasma total cell-free DNA (cfDNA) is a surrogate biomarker for tumor burden and a prognostic biomarker for survival in metastatic melanoma patients","volume":"88","author":"Valpione","year":"2018","journal-title":"Eur. J. Cancer"},{"key":"ref_121","first-page":"PO.18.00229","article-title":"Application of Circulating Cell-Free Tumor DNA Profiles for Therapeutic Monitoring and Outcome Prediction in Genetically Heterogeneous Metastatic Melanoma","volume":"3","author":"Seremet","year":"2019","journal-title":"JCO Precis. Oncol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"5926","DOI":"10.1158\/1078-0432.CCR-20-2251","article-title":"Circulating Tumor DNA Predicts Outcome from First-, but not Second-line Treatment and Identifies Melanoma Patients Who May Benefit from Combination Immunotherapy","volume":"26","author":"Marsavela","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_123","doi-asserted-by":"crossref","unstructured":"Marsavela, G., Johansson, P.A., Pereira, M.R., McEvoy, A.C., Reid, A.L., Robinson, C., Warburton, L., Khattak, M.A., Meniawy, T.M., and Amanuel, B. (2020). The Prognostic Impact of Circulating Tumor DNA in Melanoma Patients Treated with Systemic Therapies-Beyond BRAF Mutant Detection. Cancers, 12.","DOI":"10.3390\/cancers12123793"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"101072","DOI":"10.1016\/j.tranon.2021.101072","article-title":"The prognostic value of circulating tumor DNA in patients with melanoma: A systematic review and meta-analysis","volume":"14","author":"Feng","year":"2021","journal-title":"Transl. Oncol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1111\/pcmr.12623","article-title":"Feasibility of monitoring advanced melanoma patients using cell-free DNA from plasma","volume":"31","author":"Gangadhar","year":"2018","journal-title":"Pigment. Cell Melanoma Res."},{"key":"ref_126","doi-asserted-by":"crossref","unstructured":"Olbryt, M., Rajczykowski, M., Bal, W., Fiszer-Kierzkowska, A., Cortez, A.J., Mazur, M., Suwi\u0144ski, R., and Wid\u0142ak, W. (2021). NGS Analysis of Liquid Biopsy (LB) and Formalin-Fixed Paraffin-Embedded (FFPE) Melanoma Samples Using Oncomine\u2122 Pan-Cancer Cell-Free As-say. Genes, 12.","DOI":"10.3390\/genes12071080"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"5480","DOI":"10.1158\/1078-0432.CCR-16-0613","article-title":"Circulating Tumor DNA as an Early Indicator of Response to T-cell Transfer Immunotherapy in Metastatic Melanoma","volume":"22","author":"Xi","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_128","doi-asserted-by":"crossref","unstructured":"Forthun, R.B., Hovland, R., Schuster, C., Puntervoll, H., Brodal, H.P., Naml\u00f8s, H.M., Aasheim, L.B., Meza-Zepeda, L.A., Gjertsen, B.T., and Knappskog, S. (2019). ctDNA detected by ddPCR reveals changes in tumor load in metastatic malignant melanoma treated with bevacizumab. Sci. Rep., 9.","DOI":"10.1038\/s41598-019-53917-5"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.1038\/s41591-022-02015-7","article-title":"Clinical and molecular response to tebentafusp in previously treated patients with metastatic uveal melanoma: A phase 2 trial","volume":"28","author":"Carvajal","year":"2022","journal-title":"Nat. Med."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"8839","DOI":"10.1038\/ncomms9839","article-title":"Cerebrospinal fluid-derived circulating tumor DNA better represents the genomic alterations of brain tumors than plasma","volume":"6","author":"Mayor","year":"2015","journal-title":"Nat. Commun."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"85430","DOI":"10.18632\/oncotarget.13397","article-title":"Quanti-fication of tumor-derived cell free DNA(cfDNA) by digital PCR (DigPCR) in cerebrospinal fluid of patients with BRAFV600 mutated malignancies","volume":"7","author":"Momtaz","year":"2016","journal-title":"Oncotarget"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s11060-016-2081-5","article-title":"Tumor DNA in cerebral spinal fluid reflects clinical course in a patient with melanoma leptomeningeal brain metastases","volume":"128","author":"Li","year":"2016","journal-title":"J. Neurooncol"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1111\/pcmr.12861","article-title":"Leptomeningeal disease in melanoma patients: An update to treatment, challenges, and future directions","volume":"33","author":"Glitza","year":"2020","journal-title":"Pigment. Cell Melanoma Res."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1093\/jnen\/nly046","article-title":"Evaluating Circulating Tumor DNA From the Cerebrospinal Fluid of Patients with Melanoma and Leptomeningeal Disease","volume":"77","author":"Ballester","year":"2018","journal-title":"J. Neuropathol. Exp. Neurol."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/2\/861\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T10:32:28Z","timestamp":1759919548000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/2\/861"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,20]]},"references-count":134,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,1]]}},"alternative-id":["ijms26020861"],"URL":"https:\/\/doi.org\/10.3390\/ijms26020861","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,20]]}}}